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Pituitary Adenylate Cyclase-Activating Polypeptide
Is Upregulated in Murine Skin Inﬂammation
and Mediates Transient Receptor Potential
Vanilloid-1-Induced Neurogenic Edema
Zsuzsanna Helyes1,2,3,4, Jozsef Kun1,2,4, Nora Dobrosi5, Katalin Sándor1, Jozsef Németh6, Aniko Perkecz1,
Erika Pintér1,2,3, Krisztina Szabadﬁ2,7,{, Balazs Gaszner8, Valeria Tékus1,2, Janos Szolcsányi1,3,
Martin Steinhoff9, Hitoshi Hashimoto10,11, Dora Reglődi8 and Tamas Bíró5
Although pituitary adenylate cyclase-activating polypeptide (PACAP) was described as a key vasoregulator in
human skin, little is known about its expression in mouse skin. As it is important to investigate PACAP signaling in
translational mouse dermatitis models, we determined its presence, regulation, and role in neurogenic and non-
neurogenic cutaneous inﬂammatory mechanisms. The mRNA of PACAP and its speciﬁc receptor PAC1 was
detected with real-time PCR in several skin regions at comparable levels. PACAP-38-immunoreactivity measured
with radioimmunoassay was similar in plantar and dorsal paw skin and the ear but signiﬁcantly smaller in the
back skin. PACAP and PAC1 mRNA, as well as PACAP-38 and PAC1 protein expression, signiﬁcantly increased in the
plantar skin after intraplantar administration of capsaicin (50 μl, 100 μgml−1), an agonist of the transient receptor
potential vanilloid 1 (TRPV1) receptor, evoking chieﬂy neurogenic inﬂammation without inﬂammatory cell
accumulation. Intraplantar complete Freund’s adjuvant (CFA; 50 μl, 1mgml− 1) also increased PACAP/PAC1 mRNA
but not the PACAP peptide. Capsaicin-induced neurogenic paw edema, but not CFA-evoked non-neurogenic
swelling, was signiﬁcantly smaller in PACAP-deﬁcient mice throughout a 24-hour period. To our knowledge, we
provide previously unreported evidence for PACAP and PAC1 expression upregulation during skin inﬂammation of
different mechanisms and for its pro-inﬂammatory function in neurogenic edema formation.
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INTRODUCTION
Capsaicin (N-vanillyl-nonenamide), the pungent principle of
chili peppers, is a pharmacological tool to activate the
transient receptor potential vanilloid 1 (TRPV1) nonselective
cation channel located on 50–70% of sensory nerves. TRPV1
has a variety of endogenous activators, such as protons,
bradykinin, prostanoids, tumor necrosis factor-α, nerve
growth factor, gasotransmitters, or lipid peroxidase products
(Caterina et al., 1997). Many of these are crucial participants
of skin inﬂammatory processes. Capsaicin-sensitive sensory
nerves, which innervate multiple skin layers, exhibit “triple”
cutaneous functions. First, they mediate signal processing
of various sensory modalities including pain, itch, and
thermal sensation (afferent function). Second, in response to
their activation, they release a multitude of (mostly) pro-
inﬂammatory sensory neuropeptides (local efferent function)
(Szolcsanyi 1996a,b, 2004), which, among others, elicit
arteriolar vasodilatation, promote plasma protein leakage
from venules locally in the innervated area, and eventually
induce acute neurogenic inﬂammation (Maggi 1995; Geppetti
and Holzer 1996; Geppetti et al., 2008). These processes
participate in the pathological mechanisms of several
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inﬂammatory skin, joint, and airway diseases (Helyes et al.,
2003; Abdool and Brain, 2011). Third, peptides with systemic
anti-inﬂammatory and anti-nociceptive actions (such as
somatostatin and endomorphins) are also derived from these
ﬁbers (systemic effect “sensocrine” function) (Helyes et al.,
2004; Szolcsanyi 2004). Among the neuropeptides expressed
by capsaicin-sensitive sensory ﬁbers (e.g. calcitonin gene-
related peptide, substance P, other tachykinins), we were
particularly interested in pituitary adenylate cyclase-
activating polypeptide (PACAP). PACAP exists in two forms,
PACAP-27 and PACAP-38, the latter being predominant in
mammals. It is the most highly conserved member of the
vasoactive intestinal peptide/secretin/glucagon peptide super-
family (Miyata et al., 1989; Arimura 1998,2007; Vaudry et al.,
2009). The speciﬁc PACAP receptor is PAC1 coupled to
both Gs and Gq proteins activating adenylate-cyclase and
phospholipase C signal transduction pathways. VPAC1 and
VPAC2 receptors have similar binding abilities for both
PACAP and vasoactive intestinal peptide, and they predomi-
nantly activate adenylate-cyclase leading to cAMP increase.
PACAP and its receptors are widely distributed (Somogyvari-
Vigh and Reglodi, 2004; Vaudry et al., 2009; Tan and
Waschek, 2011); therefore, PACAP-coupled signaling
mechanisms are implicated in physiological and pathological
processes, including vascular integrity, neuronal development
and regeneration, circadian rhythm, and reproduction (Racz
et al., 2007; Ohtaki et al., 2008; Reichenstein et al., 2008;
Shimakura et al., 2008; Lenti et al., 2009; Reglodi et al., 2011,
2012; Tamas et al., 2012).
Co-existence of PACAP with other neuropeptides has been
shown with immunohistochemistry and real-time PCR (RT-
PCR) in capsaicin-sensitive neurons (Dun et al., 1996; Zhang
et al., 1997; Fahrenkrug and Hannibal 1998; Møller et al.,
1999; Hannibal and Fahrenkrug 2000). We have provided
evidence that PACAP-38 is released from these afferents both
in vitro (Nemeth et al., 2006) and in vivo into the systemic
circulation (Helyes et al., 2007).
Concerning its localization in the human skin, PACAP and
PAC1 have been described in nerve ﬁbers close to the
dermal–epidermal border, hair follicles, blood vessels, and
sweat glands. Their marked upregulation was observed in
psoriasis patients, indicating a role of PACAP in cutaneous
inﬂammation (Steinhoff et al., 1999).
Despite numerous studies showing an inhibitory effect of
PACAP on cellular inﬂammatory and immune processes
(Kodali et al., 2003; Gomariz et al., 2006; Peters et al., 2006;
Ding et al., 2007; Ding et al., 2012; Tan et al., 2013), little is
known about its actions on neurogenic inﬂammatory compo-
nents. We have shown that exogenous PACAP inhibits
sensory neuropeptide release and acute neurogenic inﬂam-
mation (Nemeth et al., 2006; Helyes et al., 2007). Studies with
PACAP-deﬁcient mice are useful in elucidating the function of
endogenous PACAP in inﬂammatory reactions in vivo.
Increased inﬂammatory reactions have been demonstrated
in PACAP knockout mice in colitis, autoimmune encephalo-
myelitis, airway models, neuroinﬂammation, and allergic
contact dermatitis models (Armstrong et al., 2008; Azuma
et al., 2008; Nemetz et al., 2008; Tan et al., 2009, Elekes
et al., 2011, Kemény et al., 2010; Abad and Waschek, 2011;
Reglodi et al., 2012).
As there is no information on the expression, inﬂammation-
induced alterations, and functions of PACAP in mouse skin,
our aim was to provide data for these points with radio-
immunoassay and molecular biological techniques. In order
to investigate a direct relationship between TRPV1 and PACAP
signaling, functional tests were performed in two acute in vivo
cutaneous inﬂammation models of distinct neurogenic and
non-neurogenic mechanisms using gene-deﬁcient mice.
RESULTS
PACAP and PAC1 are expressed in the mouse skin
Speciﬁc PACAP mRNA transcripts were detected in different
skin regions. Its relative mRNA expression compared with
GAPDH gene was similar in the examined regions, albeit
PACAP mRNA measured in the back skin was slightly, yet not
signiﬁcantly, smaller than in other areas. As anticipated, levels
of PACAP-38 mRNA were about 4–5-fold higher in the
hypothalamus and the pituitary gland, used as positive control
tissues (Figure 1a). Similarly to the peptide itself, we could
also identify the speciﬁc PACAP receptor, PAC1, in the mouse
skin. Its speciﬁc mRNA also showed a relatively stable
expression in different skin areas (Figure 1b).
PACAP-38 immunoreactivity (IR) was reliably measured in
the homogenates of different mouse skin samples. Its
concentration was relatively similar (20–25 fmol mg− g wet
tissue) in the plantar and dorsal paw skin, as well as the ear.
However, the amount of PACAP-IR was signiﬁcantly smaller,
7–8 fmol mg− 1, in the back skin (Figure 2a).
As the plantar skin showed considerable PACAP expression
and this is a suitable region for mouse inﬂammation
models, we analyzed this area for speciﬁc PAC1-IR. PAC1
was detected in the papillary layer of the plantar skin
(Figure 2b), where the superﬁcial vessels and sensory nerve
endings for sensing thermal, pain, and tactile stimuli are
localized (De Falco et al., 2014).
Expression levels of PACAP and PAC1 are differentially
modulated by capsaicin and CFA
Next, we assessed whether a predominantly neurogenic
inﬂammation induced by intraplantar injection of capsaicin
or a chieﬂy non-neurogenic cutaneous inﬂammation evoked
by complete Freund’s adjuvant (CFA) affects the expression
levels of PACAP and/or PAC1. PACAP mRNA expression in
the inﬂamed plantar skin samples slightly increased 4 hours
after capsaicin administration, which reached a signiﬁcant,
2.1-fold elevation at 24 hours. Meanwhile, PACAP mRNA
increase was signiﬁcant (1.6-fold) already 4 hours following
CFA injection, and it was upregulated (4.6-fold) at the 24-h
time point (Figure 3a).
PAC1 mRNA similarly increased in response to both
capsaicin and CFA at the 4 hours time point by 1.6- and
2-fold, respectively. This moderate, but statistically signiﬁ-
cant, expressional elevation remained stable (1.7-fold) 24
hours after capsaicin but increased further (5.4-fold) in case of
CFA (Figure 3b). In order to compare PACAP and PAC1
mRNA alterations with the cellular component of the
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inﬂammatory reaction, we in parallel determined the widely
expressed inﬂammatory cytokine tumor necrosis factor (TNF)-
α mRNA in the respective skin samples. Expression of TNF-α
was not signiﬁcantly altered in case of the capsaicin-induced
neurogenic inﬂammation, but it showed a signiﬁcant 2.5-fold
increase 24 hours after CFA administration (Figure 3c). It
should be noted that both expressions of PACAP and PAC1
mRNA, referring to their local synthesis, as well as that of
TNF-α were signiﬁcantly greater in the case of the non-
neurogenic CFA-induced inﬂammation compared with the
“purely” neurogenic capsaicin-evoked reaction (Figure 3a–c).
At the peptide level, capsaicin elicited a signiﬁcant, more
than 2-fold increase in PACAP-IR in the plantar skin 24 hours
post injection compared with the contralateral non-inﬂamed,
vehicle-treated side. Unexpectedly, CFA injection into the
plantar surface of the paw did not inﬂuence the total PACAP
peptide quantity in the skin samples (Figure 4a). In agreement
with the quantitative real-time PCR (qRT-PCR) results,
immunohistochemistry revealed that the effect of capsaicin
to evoke swelling of the plantar skin was accompanied by
signiﬁcantly increased PAC1-IR. Similarly, CFA treatment also
upregulated the protein level of PAC1 when compared with
non-inﬂamed vehicle-treated tissues (Figure 4b).
PACAP and TRPV1 gene-deﬁcient mice exhibit smaller
neurogenic but not non-neurogenic edema response
We then intended to assess the putative mechanism of action
of capsaicin with the help of PACAP and TRPV1 gene-
deﬁcient mice. In both wild-type CD1 (background for
PACAP− /−) and C57BL/6 (background for TRPV1− /−) wild-
type mice, the potent and selective TRPV1 receptor agonist
capsaicin evoked paw swelling, which reached its maximum
of 25–30% 2 hours after the intraplantar injection, then it
gradually decreased to 5–10% during the 24 hours of the
study (Figure 5a and b). Notably, this acute capsaicin-induced
neurogenic edema formation was signiﬁcantly smaller during
the total duration of the experiment in PACAP gene-deﬁcient
mice (Figure 5a). As expected, capsaicin did not evoke
swelling in TRPV1− /− mice (Figure 5b).
Intraplantar CFA administration also resulted in paw
edema, but this swelling had different kinetics compared
with the capsaicin effect. It reached a signiﬁcant level
(25–35% over baseline) 2 hour post injection, remained
stable for 6 hours, and then increased again to 45–55% at
24 hours in both wild-type strains. In contrast to what was
observed in the case of capsaicin, there was no measurable
difference between the extent of the CFA-evoked edema in
either PACAP or TRPV1 gene-deﬁcient mice when compared
with their respective wild types (Figure 5c and d).
The histological analysis revealed negligible dermal
edema formation and inﬂammatory cell inﬁltration in either
the capsaicin- or the CFA-treated group 4 hours after the
treatment (Supplementary Figure S1 online). Immune cells
were also absent 24 hours following capsaicin injection;
however, a signiﬁcant inﬂammatory cell accumulation (pre-
dominantly neutrophils and macrophages) was observed after
CFA application at this time point compared with its vehicle
parafﬁn oil. Although reliable morphological quantitative
evaluation was not possible on the plantar skin slides
owing to different sectioning angles and regions examined,
differences were not observed in the number of inﬁltrating
cells between the wild type and the PACAP− /− groups
(Supplementary Figure S2 online).
DISCUSSION
Despite its description as a neuro-immune modulator in
human skin (Steinhoff et al., 1999; Schwab et al., 2011), the
role of PACAP and its receptor in skin inﬂammation and
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Figure 1. Speciﬁc pituitary adenylate cyclase-activating polypeptide (PACAP) and pituitary adenylate cyclase-activating polypeptide receptor type 1 (PAC1)
mRNA transcripts are expressed in different mouse skin regions. RT-PCR determinations of PACAP and PAC1-speciﬁc mRNA transcripts, as detailed in the
Methods section. The pituitary gland (PG) and the hypothalamus (HT) served as positive controls. N, non-template control. (a) Expression of molecules in
n= 4–5 mice in each group. (b) Averaged (means± SEM) relative expression values normalized to the housekeeping gene GAPDH.
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sensory-immune communication is still poorly understood. As
PACAP is vaso- and immune-regulator, and a variety of
mechanisms and translational disease models are widely used
in mice for dermatological investigations, it is important to
map its expression in different mouse skin regions. To our
knowledge, the results demonstrate previously unreported
evidence that PACAP and its speciﬁc receptor, PAC1, can be
35
30
25
20
PA
CA
P-
38
-IR
 (fm
ol 
mg
–
1) 
15
10
5
0
Back skin Plantar skin Dorsal paw skin Ear
Figure 2. PACAP-38 and pituitary adenylate cyclase-activating polypeptide
receptor type 1 (PAC1) receptor protein are expressed in the mouse.
(a) PACAP-immunoreactivity (PACAP-IR) was determined by radioimmuno-
assay in different mouse skin regions. Columns represent means± SEM of
n= 5–6 samples obtained from different animals (the Mann–Whitney U test
vs. all other skin regions in panel a. (b) Upper panel: PAC1 protein is
expressed in the basal and polygonal layers of the epidermis (arrowheads) and
in the granular layer (arrows). The papillary layer of the dermis was positive for
PAC1 protein as well. The signal speciﬁcity is supported by the peptide pre-
absorption control experiment represented by the image taken from the
identical area of the consecutive section from the same tissue block seen in the
insert (scale bar=250 μm). Lower panel: depicts areas in higher magniﬁcation
marked by the boxes in the upper panel (scale bar=60 μm).
Non-inflamed (vehicle)
Inflamed
4h
4h
24h
24h
P <0.05
P <0.01
P <0.05P <0.05
P <0.01 P < 0.01 P <0.01
P < 0.01
P < 0.01
P < 0.01
Fo
ld
 c
ha
ng
e 
re
la
tiv
e 
to
 v
eh
icl
e
PACAP
PAC1
10
1
0.1
Fo
ld
 c
ha
ng
e 
re
la
tiv
e 
to
 v
eh
icl
e
10
1
0.1
Fo
ld
 c
ha
ng
e 
re
la
tiv
e 
to
 v
eh
icl
e 10
1
0.1
Caps CFA Caps CFA
Caps
4 h 24 h
TNFα
CFA Caps CFA
Caps CFA Caps CFA
Figure 3. Capsaicin and complete Freund’s adjuvant (CFA) upregulate
pituitary adenylate cyclase-activating polypeptide (PACAP) and pituitary
adenylate cyclaseactivating polypeptide receptor type 1 (PAC1) mRNA
expressions in the inﬂamed plantar skin. Expression of (a) PACAP and
(b) PAC1 detected by qRT-PCR in capsaicin (Caps)- and CFA-treated
plantar skin samples taken 4 and 24 hours after the induction of the
inﬂammation relative to the respective vehicle-injected contralateral tissues.
(c) The widely expressed inﬂammatory cytokine TNF-α mRNA was also
determined from the same samples to compare the peptide and the receptor
expression with the cellular components of the inﬂammation. Columns
represent means± SEM of n= 6 per group. Statistical analysis was performed
by the Mann–Whitney test versus contralateral vehicle-injected tissue.
TNF-α, tumor necrosis factor-α.
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detected in murine skin from various regions. They are also
synthesized locally besides being present on sensory nerves,
as they are detected at the mRNA level. Their relative
expressions are almost the same in dorsal and plantar paw
skin and the ear. PACAP mRNA is slightly but not signiﬁcantly
smaller in the back skin. The concentration of the PACAP-38
peptide is similar in paw skin samples and the ear but smaller
in the back skin. This might be due to a less dense sensory
innervation with less PACAP of neural origin but also to the
thicker skin and the different cutaneous structure. The
presence of PACAP has been shown in capsaicin-sensitive
sensory nerves (Moller et al., 1993; Mulder et al., 1999), hair
follicles, blood vessels, and sweat glands (Steinhoff et al.,
1999), as well as inﬂammatory and immune cells (Delgado
et al., 2003; Vaudry et al., 2009).
As a second step, we described the upregulation of locally
produced PACAP in mouse plantar skin in inﬂammatory
conditions of distinct mechanisms. Capsaicin evokes an
acute neurogenic inﬂammation by selectively activating a
subpopulation of nociceptive sensory nerves via TRPV1 and
consequently releasing several vasoactive neuropeptides
(Holzer 1988; Maggi 1995; Szolcsanyi 1996a,b,) including
PACAP. Meanwhile, CFA elicits a chronic, predominantly
non-neurogenic inﬂammatory response by triggering the
innate immune system through stimulating macrophages
and T lymphocytes and producing cellular inﬁltration with
sensory neuronal elements involved only at a later stage
(Qin et al., 1993; Wolstenholme et al., 2008). Signiﬁcant
upregulation of PACAP was observed in the plantar skin at
both mRNA and the peptide levels 24 hours after capsaicin
injection. Capsaicin selectively activates the TRPV1 channel,
which has been described not only on sensory nerves but also
on keratinocytes, dendritic cells, and sebocytes in the skin
(Toth et al., 2008, 2009). Increased PACAP expression in
response to TRPV1 activation can be explained either by its
direct effect at extraneural TRPV1 receptors or an indirect
action via the release of sensory nerve–derived inﬂammatory
mediators. Substance P and calcitonin gene-related peptide
are able to stimulate epithelial and inﬂammatory cells;
therefore, they might increase PACAP synthesis in these
structures. We have previously provided in vivo evidence that
PACAP-38 is released from capsaicin-sensitive ﬁbers of the
skin in response to systemic TRPV1 receptor stimulation
(Helyes et al., 2007). Likewise, in vitro data proved PACAP
release of these afferents upon electrical and chemical
stimulations (Nemeth et al., 2006). As capsaicin elevated
both PACAP mRNA and peptide in the skin, its local
upregulation and release from the stimulated sensory ﬁbers
are suggested. Meanwhile, CFA increased the PACAP mRNA
level signiﬁcantly more than capsaicin did at the 24 hours
time point, but interestingly it did not alter the peptide-IR. This
virtual contradiction can be explained by the fact that, at the
mRNA level, we only measure the locally synthesized non-
neural PACAP but not that of sensory neural origin (the mRNA
of which is located in the dorsal root ganglia). This represents
only a small fraction of the total peptide amount in the tissue,
and the much higher neural PACAP expression is also
supported by our ﬁndings. We propose that, in the CFA
model, the inﬁltrating and accumulating inﬂammatory cells
are the major local sources of PACAP mRNA increase by two
mechanisms: (i) increased number and/or (ii) enhanced
PACAP synthesis. However, this might not be sufﬁcient to
considerably elevate the peptide concentration compared
with the total amount measured in the skin. Another
explanation is that there was a 50% paw swelling in the
CFA model at the 24 hours time point. As the peptide IR is
normalized to the wet tissue weight, the edema-induced
greater weight might result in a smaller relative peptide
concentration.
Upregulation of PACAP has been shown in various types of
neuronal damage, such as motor nerve injury, sciatic nerve
transection and neuronal inﬂammation, and sympathetic
chain lesion, which might indicate endogenous adapt-
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ation to injuries and its possible role in regeneration.
Upregulated trophic factors and neuropeptides may be
important for post-axotomy/post-inﬂammation survival and
restoration (Somogyvari-Vigh and Reglodi, 2004).
PAC1 expression also increased in both types of inﬂamma-
tion at the mRNA and protein levels, suggesting that this target
is likely to mediate the effects of PACAP in the skin. PAC1 was
shown to be upregulated after some injuries depending on the
local microenvironment; PACAP can also induce the upre-
gulation of its receptor. Our results suggest that PACAP
signaling (both PACAP and PAC1 receptor) is stronger in both
types of inﬂammation (Somogyvari-Vigh and Reglodi, 2004).
The role of PACAP can only be determined under in vivo
experimental conditions with gene-deﬁcient mice, as stable,
selective pharmacological tools are not available. Our results
with PACAP-deﬁcient mice also revealed the in vivo func-
tional relevance of the locally increased PACAP in acute
vascular inﬂammatory responses. PACAP proved to be a
potent pro-inﬂammatory mediator, which increases edema
due to short-lasting neurogenic but not non-neurogenic
mechanisms. Intradermally injected PACAP induces plasma
extravasation in the hindpaw (Cardell et al., 1997). In
contrast, we have shown earlier that a low dose of
intraperitoneal PACAP-38 inhibits acute neurogenic plasma
leakage in the rat plantar skin evoked by TRPV1 or TRPA1
agonists and also decreased carrageenan-induced “mixed-
type” inﬂammation (Nemeth et al., 2006; Helyes et al., 2007).
This inhibitory effect was explained by the inhibition of the
release of SP/calcitonin gene-related peptide from sensory
nerves (Nemeth et al., 2006) and other inﬂammatory medi-
ators from sympathetic ﬁbers or cellular sources. Furthermore,
its direct inhibitory effect on plasma extravasation and edema
at the level of the vascular endothelium can also be assumed.
This is supported by the presence of PAC-1 on endothelial
cells (Abu-Hamdan et al., 2006), but numerous data indicate
a relaxing action of PACAP on the vascular smooth muscle
(Fahrenkrug et al., 2000; Dalsgaard et al., 2003), independent
of the endothelium (Warren et al., 1991, 1992).
On the basis of these data, the role of endogenous PACAP
in acute neurogenic edema formation in the skin is pro-
inﬂammatory, whereas the effect of the exogenous peri-
pherally administered peptide is inhibitory on sensory
neuropeptide release (Nemeth et al., 2006; Helyes et al.,
2007). This latter action is not mediated by the known PACAP
receptors, as their signaling mechanisms are all stimulatory on
the nerve terminals. This might be explained by distinct
inhibitory mechanisms and targets via different, currently not
identiﬁed, receptors or splice variants on the sensory nerves.
The role of PACAP in inﬂammation is complex. It increases
the early vascular phase by inducing vasodilatation, plasma
protein leakage from the fenestrated veins, inﬂammatory cell
extravasation, and consequent immune cell accumulation
induced both by neurogenic and non-neurogenic mechan-
isms. In contrast, it inhibits the later cellular responses by
decreasing the activation and further accumulation of
immune cells (Delgado et al., 2003; Botz et al., 2014).
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polypeptide (PACAP) and transient receptor potential vanilloid 1. Inﬂammation was induced by intraplantar injection of capsaicin (a and b) or CFA (c and d) in
gene-deﬁcient (PACAP− /−, TRPV1− /−) mice, as well as in their respective wild-type littermates (PACAP+/+, C57Bl/6 WT); the dynamics of paw swelling was
monitored at the time points. Symbols indicate % increase in the volume of the hindpaws compared with the initial values, measured with plethysmometry before
the induction of the inﬂammation. Each data point represents the mean± SEM of n=5–6 mice per group, **Po0.01 *Po0.001 versus wild-type (one-way
ANOVA followed by Bonferroni’s modiﬁed t-test) . ANOVA, analysis of variance.
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In summary, in this study, we provide evidence for the
expression and capsaicin-induced upregulation of PACAP
in murine skin both at the mRNA and peptide levels.
Furthermore, using PACAP and TRPV1 gene-deﬁcient mice,
we demonstrate that PACAP is a regulator of TRPV1-mediated
acute neurogenic edema formation. The role of PACAP in
chronic inﬂammatory skin diseases and its human relevance
awaits further clariﬁcation.
MATERIALS AND METHODS
Animals
Male CD1 wild-type and PACAP gene-deleted mice (25–35 g)
(Hashimoto et al., 2006) were bred and kept in the Animal House
of the Department of Pharmacology and Pharmacotherapy,
University of Pécs, at 24–25 °C and provided with standard mouse
chow and water ad libitum. The breeding pairs of the TRPV1 receptor
gene-deleted mice (TRPV1− /−) and C57Bl/6 wild-types were from
Jackson Laboratories (Bar Harbor, ME).
Animals were killed by cervical dislocation under ketamine-
xylazine (100 mg kg−1-5 mg kg− 1 intraperitoneal) anesthesia; the
skin samples were excised and cut into three parts: (i) stored in
RNA later for molecular biological studies, (ii) frozen at − 20 °C for
radioimmunoassay, and (iii) put into 4% paraformaldehyde for
immunohistochemistry.
Experiments were carried out according to the 1998/XXVIII Act of
the Hungarian Parliament on Animal Protection and Consideration
Decree of Scientiﬁc Procedures of Animal Experiments (243/1988)
and complied with the recommendations of the International
Association for the Study of Pain. The experiments were approved
by the Ethics Committee on Animal Research of the University of
Pécs (license number: BA02/2000-2/2012).
Measurement of PACAP, PAC1, and TNF-α mRNA in the skin
Expressions of PACAP (Adcyap1, GenBank Accession: NM_009625)
and PAC1 (Adcyap1r1, NM_007407, NM_001025372)-speciﬁc
mRNA were determined by semi-quantitative RT-PCR in different
mouse skin samples (Bodó et al., 2004; Dobrosi et al., 2008). Total
RNA was isolated with TRIzol. One μg of total RNA was then reverse
transcribed into cDNA by using 15U of AMV reverse transcriptase
and 0.025 μg μl− 1 random primers. Subsequent PCR ampliﬁcation
(95 °C for 2 minutes, 35 cycles of 94 °C for 1 minute; 61.5 °C for
PACAP for 1 minute, 62.5 °C for PAC1 for 90 seconds, 55.5 °C for
GAPDH for 60 seconds, 72 °C for 1 minute; 72 °C for 2 minutes) was
performed on the GeneAmp PCR System 2400 DNA Thermal Cycler
(Applied Biosystems, now Thermo Fisher Scientiﬁc, Waltham, MA).
Primers were synthesized by Invitrogen (now Thermo Fisher
Scientiﬁc) (PACAP, forward: 5′-GGGGCAAGTCTAGCTCCTCT-3′,
PACAP, reverse: 5′-GGGTCTCCAGAAAATCCACA-3′, product: 225 bp;
PAC1, forward: 5′-AGGCAATGAGTCGAGCATCT-3′, reverse: 5′-GT
CTTTCCCTCTTGCTGACG-3′, product: 220 bp; Glyceraldehyde
3-phosphate dehydrogenase (Gapdh, NM_001289726, NM_008084),
forward: 5′-ATGGTGAAGGTCGGTGTGAAC-3′; reverse: 5′-GCTGA
CAATCTTGAGGGAGT-3′, product: 459 bp). PCR products were
visualized on a 1.5 agarose gel with ethidium bromide (0.5 mgml−1)
under UV, and the photographed bands were quantiﬁed by an Image
Pro Plus 4.5.0 software (Media Cybernetics, Rockville, MD).
The expression of PACAP (Adcyap1), PAC1 (Adcyap1r1), and TNF-
α (Tnf, NM_013693, NM_001278601) mRNA was determined by
quantitative real-time PCR in capsaicin and CFA-treated plantar skin
samples. PCR ampliﬁcation (two-step protocol: 95 °C for 10minutes;
40 cycles of 95 °C for 30 seconds and 60 °C for 1 minute)
was performed on the Stratagene MX3000P system (Agilent
Technologies, Santa Clara, CA). Primers: PACAP, forward: 5′-GACC
AGAAGACGAGGCTTACG-3′, reverse: 5′-GTCCGCTGGATAGTAA
AGGGC-3′, product: 128 bp; PAC1, forward: 5′-GAGAACGTCA
GCAAGAGGGA-3′, reverse: 5′-GCCTGTACCTCCCCATTCAG-3′,
product: 107 bp; TNFα, forward: 5′- CAGGCGGTGCCTATGTCTC-3′,
reverse: 5′-CGATCACCCCGAAGTTCAGTAG-3′, product: 89 bp;
Gapdh, forward: 5′-AATGGTGAAGGTCGGTGTG-3′, reverse:
5′-GTGGAGTCATACTGGAACATGTAG-3′, product: 150 bp. The
reference gene Gapdh was used as an internal control. Samples
were measured in duplicates, and Ct values were averaged to reduce
technical variability. Fold changes were calculated by the ΔΔCt
method and standardized as described by Willems et al. (2008).
Determination of PACAP-38 with radioimmunoassay
PACAP-38-like IR was determined with a speciﬁc and sensitive
radioimmunoassay technique developed in our laboratory and
described earlier in detail (Jakab et al., 2004; Nemeth et al., 2006).
In brief: Antiserum: “88111-3” (working dilution 1:10,000).
Tracer: mono-125I-labeled ovine PACAP 24–38 prepared in our
laboratory (5,000 cpm per tube). Standard: ovine PACAP-38 was
used as a radioimmunoassay standard ranging from 0 to 1,000
fmol ml−1. Buffer: the assay was prepared in 1ml 0.05mol l− 1
(pH 7.4) phosphate buffer containing 0.1 mol l−1 sodium
chloride, 0.25 w/v % BSA, and 0.05 w/v % sodium azide. Incu-
bation time: 48–72 h incubation at 4 °C. Separation solution:
charcoal/dextran/milk powder (10:1:0.5 g in 100ml distilled
water). PACAP-38 concentrations of the unknown samples were
read from a calibration curve; detection limit of the assay was
2 fmol ml−1.
Histology, immunohistochemistry
Plantar skin samples were ﬁxed in 4% paraformaldehyde for 1 hour
at room temperature, and serial histological sections were prepared.
The specimens were rinsed in phosphate-buffered saline, permeabi-
lized in 0.1% Triton X-100 for 5 minutes, and incubated with
0.1% BSA, 1% normal goat serum, and 0.1% Na-azide for 1 hour
to minimize nonspeciﬁc labeling. Sections were incubated
overnight at room temperature with anti-PAC1 antibody raised in
rabbit (1:100, given by Seiji Shioda). For semi-quantitative purposes,
sections were incubated for 2 hours in the dark with the correspond-
ing Alexa Fluor “568” secondary antibody, raised in goat (1:1,000),
and mounted with Fluoromount-G. Digital photographs were taken
with a Nikon Eclipse 80i microscope (Tokyo, Japan). PAC1 intensity
was measured with the ImageJ 1.440 software; expression levels
were corrected with the tissue background (standard duration,
settings, unit range: 250× 250 pixels, 10 measurements/slide
averaged).
For qualitative purposes, the 3,3’-diaminobezidine technique was
preferred. The same protocol was used, but after the same primary
antibody, the sections were incubated in biotinylated goat anti-rabbit
serum (1:200) for 1 hour at room temperature and transferred into the
avidin-biotin complex for 1 hour. The immunoreaction was devel-
oped in 0.02% 3,3’-diaminobezidine in Tris buffer with 0.00003%
H2O2, for 10 minutes. Sections were mounted on gelatin-coated
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slides, treated with for 2× 10minutes with xylene, and covered with
DePex. To test the speciﬁcity of the antibodies, some sections were
treated by non-immune goat serum instead of the primary or
secondary antibody. In addition, in three separate vials, the 1:100
diluted primary antiserum was pre-incubated for 2 hours at room
temperature with 0.1, 1, or 10 μg of synthetic (blocking) peptide, to
which the PAC1 antibody was raised. After development, immuno-
reaction signal was not observed in either cases, and the pre-
absorption peptide completely abolished the immunolabeling in all
three cases.
Induction and assessment of acute paw inﬂammation
Neurogenic and mixed-type inﬂammatory reactions were evoked by
intraplantar injection of 50 μl capsaicin (100 μgml−1) or complete
Freund’s adjuvant (CFA, killed Mycobacteria tuberculosis suspended
in parafﬁn oil; 50 μl, 1 mgml−1) into the left hindpaw, respectively.
The respective solvents were injected in the same volume into the
contralateral paw. Mice were killed in deep anesthesia 4 or 24 hours
after capsaicin or CFA. The plantar skin of the hindpaws was
removed and cut into half for further PCR and radioimmunoassay
processing, as described.
To assess the role of PACAP and TRPV1 in paw swelling induced
by inﬂammatory stimuli, such as capsaicin and CFA activating
distinct inﬂammatory mechanisms, the paw volume was measured
with plethysmometry (Ugo Basile, Gemonio, Italy) before and
repeatedly after the induction of the inﬂammation. Edema was
expressed as % of initial control (n= 6–8/group).
Statistical analysis
Statistical evaluation of plasma PACAP-IR and mRNA data was
performed with the Mann–Whitney U-test. For analyzing the results
in the inﬂammation experiments (edema, PACAP/PAC1 immunor-
eactivities), analysis of variance+Bonferroni’s t-test was used
(Po0.05 was considered signiﬁcant).
Drugs and chemicals
PACAP-38, capsaicin (8-methyl-N-vanillyl-6-nonenamide), CFA, and
ethidium bromide were obtained from Sigma (St Louis, MO), ethanol
and Tween 80 from Reanal (Budapest, Hungary), ketamine from
Richter Gedeon (Budapest, Hungary) and xylazine from Eurovet
Animal Health BV (Bladel, The Netherlands), RNA-later from Qiagen
(Hilden, Germany), TRIzol and primers from Invitrogen (now part of
Thermo Fisher Scientiﬁc, Renfrew, UK), AMV reverse transcriptase
from Promega (Madison, WI), and Thermal Cycler from Applied
Biosystems (now part of Thermo Fisher Scientiﬁc). Alexa Fluor “568”
secondary antibody and Fluoromont-G were purchased from South-
ern Biotech (Birmingham, AL), biotinylated goat anti-rabbit serum
and the avidin-biotin complex (Vectastain Elite ABC Kit) from Vector
Laboratories (Burlingame, CA), and DePex from Fluka (Germany).
Capsaicin was dissolved in 10% ethanol, 10% Tween 80, and 80%
saline (0.9% NaCl) to a 10mgml−1 stock solution and further diluted
with saline. PACAP-38 antiserum was provided by Prof. A. Arimura
(Tulane University, New Orleans, LA).
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